BELTSVILLE, MD--(Marketwire - December 12, 2011) - BioServe today announced an expanded relationship with Fox Chase Cancer Center, a foundation member of the BioServe Network of leading sample biorepositories. In this expanded relationship, BioServe will be working with Fox Chase to provide clients with next generation sequencing capabilities. Fox Chase has outfitted a new internal laboratory utilizing next-generation sequencing and analysis platforms and novel biological information technology systems for advanced analysis of genomic data.
"We are excited offer our customers next generation sequencing through Fox Chase. BioServe is uniquely positioned to be a single partner that can provide high quality human tissue samples and generate validated data from those samples to accelerate discovery," said Rama Modali, President, BioServe.
"Accessing our industrial scale BioRepository of individual patient DNA, RNA and serum, researchers can leverage our genomic services to interrogate the entire biological spectrum -- genome, transcriptome and metabolome.
In particular, BioServe's BioRepository contains high-quality, high-yield DNA ready for next generation sequencing analysis, for example:
- Cardiovascular disease - 27,000 patients
- Diabetes - 12,000 patients
- Arthritis - 7,500 patients
- Asthma - 3,000 patients
- Normal, healthy controls - 12,000 donors
In addition, BioServe has high quality samples ready for cancer genome analysis:
- Tumor DNA from 3,000 patients
- Matched pairs samples (tumor + normal adjacent tissue) from 300 donors in breast and colon, 160 donors in lung cancer, 200 donors in gastric cancer, 60 uterine cancer
"Life science research firms can now obtain high quality human samples from our BioRepository and sample Network, as well as use BioServe for sample preparation, extraction, genotyping and now next generation sequencing. There are few service providers who can now match our breadth and quality of genomic service offerings," Modali added.
"Fox Chase is focused on using genomic sequencing to help develop personalized medicine strategies for cancer care. To this end, we have outfitted our capabilities with the most advanced sequencing and analysis capabilities," said Dr. Kurt Schwinghammer, Vice President of Research & Development Alliances, Fox Chase. "This expanded relationship with BioServe will enable their customers to validate targets and generate the insight needed to develop new and improved cancer treatments."
BioServe provides a comprehensive 'biomaterial to validated data' genomics services platform, helping researchers gain the pre-clinical data for breakthroughs in drug discovery, molecular diagnostics and pharmacogenomics. Utilizing BioServe's genomics services platform, researchers can identify genetic markers, validate drug targets and correlate clinical data with molecular data to accelerate the development of new and safer drugs. BioServe's services extend from nucleic acids processing, DNA synthesis, high throughput genotyping, genome wide-scans and gene expression analyses to ready-made large epidemiologically sound case-control studies of inflammatory disorders, endocrine disorders, cardiovascular disease, diabetes, hypertension, obesity and many cancers. BioServe's Global BioRepository provides researchers with a library of 600,000 human DNA, tissue and serum samples linked to detailed clinical and demographic data from 120,000 consented and anonymized patients from four continents.
For more information please visit www.bioserve.com or call 301-470-3362.
About Fox Chase Cancer Center:
Fox Chase Cancer Center is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation's first cancer hospitals, Fox Chase was among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are routinely recognized in national rankings, and the Center's nursing program has received the Magnet status for excellence three consecutive years. Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, visit Fox Chase's web site at www.foxchase.org or call 1-888-FOX CHASE or (1-888-369-2427).
For more information, call 1-888-FOX-CHASE or 1-888-369-2427.